A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached stat
Johnson & Johnson has reported positive phase 3 data with Darzalex in smouldering multiple myeloma (SMM), just before filing applications for the drug in this indication in Europe and t
It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the firs
Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential.
